Actuate Therapeutics Inc
ACTUHealthcare|Biotechnology|US
$0.33
+0.00 (+0.55%)
DCF Value
$0.54
Tangible Book / Share
$0.04
Cash / Share
$0.19
Financials
Financial Snapshot
Market Cap
$7.9M
Enterprise Value
$3.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$20.5M
Cash & Investments
$4.4M
Net Cash
$4.0M
Free Cash Flow (TTM)
-$19.8M
Operating CF (TTM)
-$19.8M
Debt/Equity
0.41
Cash Runway & Burn Rate
Cash on Hand
$4.4M
Quarterly Burn
$5.0M
Monthly Burn
$1.7M
Est. Runway
~0.9 quarters
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $20.4M | $3.0M | $8.6M | $13.2M | $4.4M | |
| Operating Cash Flow | -$17.8M | -$21.6M | -$21.8M | -$19.2M | -$19.8M | |
| Free Cash Flow | -$17.8M | -$21.6M | -$21.8M | -$19.2M | -$19.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $19.3M | $4.1M | $27.5M | $23.7M | $17.8M |
R&D Spending
R&D (TTM)
$8.9M
R&D Intensity
—
R&D Growth vs Prior
-13.1%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $16.4M | $21.7M | $18.7M | $10.3M | $8.9M | |
| SG&A | $3.8M | $3.3M | $6.5M | $12.2M | $11.8M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $16.4M | $21.7M | $18.7M | $10.3M | $8.9M | |
| SG&A | $3.8M | $3.3M | $6.5M | $12.2M | $11.8M | |
| Operating Income | -$20.2M | -$25.0M | -$25.2M | -$22.5M | -$20.8M | |
| Interest Expense | $16.2K | $43.6K | -$18.7K | $20.3K | $20.3K | |
| Pretax Income | -$20.2M | -$24.7M | -$27.3M | -$22.2M | -$20.5M | |
| Net Income | -$20.2M | -$24.7M | -$27.3M | -$22.2M | -$20.5M | |
| EPS (Diluted) | -1.34 | -1.65 | -3.26 | -1.06 | -0.89 | |
| EBITDA | $63.6K | $272.8K | -$2.1M | -$22.2M | -$20.5M | |
| Shares Out. (M) | 15.03 | 15.03 | 19.51 | 21.02 | 23.87 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.4M | $3.0M | $8.6M | $13.2M | $4.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $20.5M | $3.0M | $9.2M | $13.6M | $4.7M | |
| Total Assets | $20.5M | $3.0M | $9.3M | $14.0M | $5.2M | |
| Total Current Liabilities | $4.3M | $6.9M | $8.8M | $5.7M | $3.8M | |
| Long-Term Debt | $405.0K | $0.00 | $0.00 | $405.0K | $405.0K | |
| Total Liabilities | $5.7M | $102.6M | $9.2M | $6.1M | $4.2M | |
| Stockholders' Equity | $14.8M | -$99.6M | $104.2K | $7.9M | $989.2K | |
| Retained Earnings | -$80.3M | -$105.1M | -$132.4M | -$154.6M | -$165.1M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.8M | -$21.6M | -$21.8M | -$19.2M | -$19.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$17.8M | -$21.6M | -$21.8M | -$19.2M | -$19.8M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $19.3M | $4.1M | $27.5M | $23.7M | $17.8M | |
| Issuance of Stock | $0.00 | $0.00 | $24.0M | $24.0M | $18.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $5.5M | $0.00 | $0.00 | |
| Stock Based Comp. | $654.1K | $423.5K | $2.0M | $6.0M | $6.0M | |
| Net Change in Cash | $1.5M | -$17.5M | $5.7M | $4.5M | -$2.1M |
Dilution Tracker
Shares outstanding grew 39.8% over 5 years — significant dilution
Shares Outstanding
24M
5-Year Share Growth
+39.8%
Stock Issuance (TTM)
$18.4M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 15.03 | 15.03 | 19.51 | 21.02 | 23.87 | |
| Change vs Prior % | — | 0.0% | 29.8% | 7.7% | 13.6% | |
| Stock Issuance | $0.00 | $0.00 | $24.0M | $24.0M | $18.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $654.1K | $423.5K | $2.0M | $6.0M | $6.0M |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| ROE % | -135.9% | 24.8% | -26189.1% | -280.5% | -346.2% | |
| ROA % | -98.4% | -826.0% | -292.8% | -158.4% | -393.4% | |
| ROIC % | -125.2% | 636.3% | -4876.6% | -270.1% | -1490.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -23.6% | -0.7% | 10.6% | |
| Net Income | 0.0% | -22.7% | -10.3% | 18.5% | |
| EPS (Diluted) | 0.0% | -23.1% | -97.6% | 67.5% | |
| Operating Cash Flow | 0.0% | -21.5% | -1.0% | 12.1% | |
| Free Cash Flow | 0.0% | -21.5% | -1.0% | 12.1% | |
| R&D Expense | 0.0% | 32.5% | -14.0% | -44.9% | |
| SG&A Expense | 0.0% | -14.5% | 98.6% | 88.2% | |
| Total Assets | 0.0% | -85.4% | 211.1% | 50.6% | |
| Book Value / Share | 0.0% | -771.7% | 100.1% | 6960.4% | |
| Debt | 0.0% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 29.8% | 7.7% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B7.94
10Y Low / Med / High8.73 / 16.24 / 1490.96
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.54
Tangible Book / Share
$0.04
Net Current Assets / Share
$0.02
Graham Net-Net
$0.01
Cash / Share
$0.19
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| P/E Ratio | -6.43 | -5.22 | -2.44 | -5.77 | -0.37 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 8.73 | -1.30 | 1490.96 | 16.24 | 7.94 | |
| EV/EBITDA | 1719.90 | 463.56 | -68.44 | -5.22 | -0.19 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-56.11
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $6.2M | $33.4M |
| Net Income | -$15.3M | -$13.8M | -$14.5M |
| EPS | $-0.73 | $-0.66 | $-0.69 |
| # Analysts (EPS) | 2 | 2 | 1 |